Sven Vilhelm Eriksson

Sven Vilhelm Eriksson

Auto-generated profile, based on publicly available information

Sven Vilhelm Eriksson

Department of Medicine, Danderyds Hospital, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1996 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NRN. Rehnqvist
N. Rehnqvist
PHP. Hjemdahl
P. Hjemdahl
EBE. Billing
E. Billing
IBI. Bjorkander
I. Bjorkander
SES. V. Eriksson
S. V. Eriksson
NWN. H. Wallen
N. H. Wallen
To study long-term treatment effects of metoprolol or verapamil on combined cardiovascular end points and psychological variables in patients with stable angina pectoris. Randomized, double-blind, double-dummy trial. The study included 809 patients under 70 years of age with stable angina pectoris. The mean age of the patients was 59 ± 7 years and 31% were women. Exclusion criteria were myocardial infarction within the previous 3 years and contraindications to beta-blockers and calcium antagonists. The patients were followed between 6 and 75 months (median 3.4 years and a total of 2887 patient years). The patients were treated with either metoprolol (Seloken ZOC 200 mg o.d.) or verapamil (Isoptin Retard 240 b.i.d.). Acetylsalicylic acid, ACE inhibitors, lipid lowering drugs and long acting nitrates were allowed in the study. Death, non-fatal cardiovascular events including acute myocardial infarction, incapacitating or unstable angina, cerebrovascular or peripheral vascular events. Psychological variables reflecting quality of life i.e. psychosomatic symptoms, sleep disturbances and an evaluation of overall life satisfaction. Combined cardiovascular events did not differ and occurred in 30.8% and 29 3% of metoprolol and verapamil treated patients respectively. Total mortality in metoprolol and verapamil treated patients was 5.4 and 6.2%, respectively. Cardiovascular mortality was 4.7% in both groups. Non-fatal cardiovascular events occurred in 26.1 and 24.3% of metoprolol and verapamil-treated patients, respectively. Psychosomatic symptoms and sleep disturbances were significantly improved in both treatment groups. The magnitudes of change were small and did not differ between treatments. Life satisfaction did not change on either drug. Withdrawals due to side effects occurred in 11.1 and 14.6%, respectively. This long term study indicates that both drugs are well tolerated and that no difference was shown on the effect on mortality, cardiovascular end points and measures of quality of life.

1 January 2001 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CHC. Held
C. Held
PHP. Hjemdahl
P. Hjemdahl
SES.V. Eriksson
S.V. Eriksson
IBI. Björkander
I. Björkander
LFL. Forslund
L. Forslund
NRN. Rehnqvist
N. Rehnqvist
Background Ultrasonographic assessments of intima-media thickness and plaques in the carotid artery are widely used as surrogate markers for coronary

1 January 1991 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
MTM. Thomas
M. Thomas
SES. V. Eriksson
S. V. Eriksson
TLT. Lundeberg
T. Lundeberg

20 May 1997 in Circulation
Verified
Journal Article
Closed access
CHClaes Held
Claes Held
PHPaul Hjemdahl
Paul Hjemdahl
NRNina Rehnqvist
Nina Rehnqvist
NWN. HåkAn Wallén
N. HåkAn Wallén
IBInge BjörKander
Inge BjörKander
BWBjörN Wiman
BjörN Wiman
Background Disturbed fibrinolytic function may influence the progression of coronary atherosclerosis and contribute to thrombotic cardiovascular (CV) events. Methods and Results In the Angina Prognosis Study In Stockholm (APSIS), patients with stable angina pectoris were studied prospectively during double-blind treatment with metoprolol or verapamil. Various measures of fibrinolytic function were studied in 631 (of 809) patients. During a median follow-up time of 3.2 years (2132 patient-years), 32 patients suffered a CV death, 21 had a nonfatal myocardial infarction (MI), and 77 underwent revascularization. Plasma levels of tissue plasminogen activator (TPA) activity and antigen (ag), plasminogen activator inhibitor (PAI-1) activity at rest, and TPA responses to exercise were determined at baseline and after 1 month's treatment and were related to subsequent fatal and nonfatal CV events. Univariate Cox regression analysis revealed that elevated levels of TPA-ag at rest ( P <.05), high PAI-1 activity ( P <.05), and low TPA-ag responses to exercise ( P <.05) were associated with increased risk of subsequent CV death. After adjustment for baseline risk factors, TPA-ag independently predicted CV death or MI. In addition, PAI-1 activity independently predicted CV death or MI in male patients. Verapamil treatment was associated with a 10% decrease of TPA-ag levels and metoprolol treatment with a 2% increase ( P <.001 for treatment difference). Conclusions Plasma TPA-ag levels at rest, and among male patients PAI-1 activity as well, independently predict subsequent CV death or MI in patients with stable angina pectoris. Impaired fibrinolytic reactivity to exercise is a novel factor related to CV prognosis. Effects of verapamil or metoprolol treatment on fibrinolytic function did not importantly influence CV prognosis.

1 February 2006 in Heart
Verified
Journal Article
Closed access
PDF file
PHP Hjemdahl
P Hjemdahl
SES V Eriksson
S V Eriksson
CHC Held
C Held
LFL Forslund
L Forslund
PNP Näsman
P Näsman
NRN Rehnqvist
N Rehnqvist
Objective: To evaluate the long term prognosis of patients with stable angina pectoris. Design: Registry based follow up (median 9.1 years) of patients participating in the APSIS (angina prognosis study in Stockholm), which was a double blind, single centre trial of antianginal drug treatment. Patients: 809 patients (31% women) with stable angina pectoris < 70 (mean (SD) 59 (7) years at inclusion) and an age and sex matched reference population from the same catchment area. Interventions: Double blind treatment with metoprolol or verapamil during 3.4 years (median), followed by referral for usual care with open treatment. Main outcome measures: Cardiovascular (CV) death and non-fatal myocardial infarction (MI) in the APSIS cohort and total mortality in comparison with reference subjects. Results: 123 patients died (41 MI, 36 other CV causes) and 72 had non-fatal MI. Mortality (19% v 6%, p<0.001) and fatal MI (6.6% v 1.6%, p < 0.001) were increased among male compared with female patients. Diabetes, previous MI, hypertension, and male sex independently predicted CV mortality (p < 0.001). Diabetes greatly increased the risk in a small subgroup of female patients. Male patients had higher mortality than men in the reference population during the first three years (cumulative absolute difference 3.8%) but apparently not thereafter. Female patients had similar mortality to women in the reference population throughout the 9.1 years of observation. Conclusions: Female patients with stable angina had similar mortality to matched female reference subjects but male patients had an increased risk. Diabetes, previous MI, hypertension, and male sex were strong risk factors for CV death or MI.

1 November 1994 in Clinical Cardiology
Verified
Journal Article
Closed access
PDF file
SES. V. Eriksson
S. V. Eriksson
PEP. Eneroth
P. Eneroth
JKJ. Kjekshus
J. Kjekshus
JOJ. Offstad
J. Offstad
KSK. Swedberg
K. Swedberg